Related Experiment Videos
[Multicenter study of Klimonorm (R) by the Jenapharm firm for treating the climacteric syndrome]
R Czekanowski1, J Stelmachow, S Radowicki
1Szpitala Ginekologiczno-Połozniczego, Warszawie.
Ginekologia Polska
|April 1, 1995
Summary
Klimonorm effectively reduced menopausal symptoms in women over six months. The estrogen-progestagen therapy showed no adverse effects on blood pressure or weight, with high patient satisfaction and intent to continue treatment.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
Background:
- Menopause is associated with various signs and symptoms.
- Hormone replacement therapy (HRT) is a common treatment for menopausal symptoms.
Purpose of the Study:
- To evaluate the effectiveness and safety of Klimonorm, an estrogen-progestagen preparation, in treating menopausal symptoms.
Main Methods:
- A 6-month observational study involving 116 women.
- The Kupperman Index was used to assess menopausal symptom severity.
- Blood pressure and body weight were monitored.
Main Results:
- Significant reduction in the mean Kupperman Index from 28.38 to 11.6 after 3 months and 5.47 after 6 months.
- No observed increase in blood pressure or body weight during the 6-month observation period.
- High patient satisfaction: 93.21% rated Klimonorm as very good or good.
- Good tolerability: 91.43% and 91.59% reported very good or good tolerance.
Conclusions:
- Klimonorm is an effective and well-tolerated treatment for menopausal signs and symptoms.
- The therapy demonstrates a favorable safety profile regarding blood pressure and body weight.
- The majority of patients expressed a desire to continue Klimonorm treatment.